touchONCOLOGY joins Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at EHA25 Virtual to discuss the ANDROMEDA study (NCT03201965), and the efficacy and safety of daratumumab in combination with CYBORD for the treatment of newly-diagnosed light chain amyloidosis.
1. What are the major therapeutic challenges in the management of patients with newly-diagnosed light chain amyloidosis? (0:04)
2. What is the rationale for the use of daratumumab in combination with CYBORD in this treatment setting? (0:36)
3. Why was daratumumab administered subcutaneously rather than intravenously? (1:40)
4. What were the primary efficacy and safety findings from the ANDROMEDA study? (2:38)
5. What is the significance of these findings and what are the next steps for this combined therapy? (3:55)
Abstract LB2604, Subcutaneous Daratumumab + Cyclophosphamide, Bortezomib, and Dexamethasone (CYBORD) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Primary Results from the Phase 3 ANDROMEDA Study, was presented as a late-breaking abstract at EHA25 Virtual and is available here.
Speaker disclosure: The ANDROMEDA study is supported by The Janssen Pharmaceutical Companies of Johnson & Johnson.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the Virtual Edition of the 25th European Hematology Association Annual Congress (EHA25 Virtual), June 2020
CYBORD = cyclophosphamide, bortezomib, and dexamethasone
